Chronic obstructive pulmonary disease
COPD · R&I · 5 drugs · 2 indications
Progressive lung disease with airflow obstruction.
Competitive Landscape (5 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| Itepekimab | REGN | IL-33 inhibitor | Monoclonal antibody | SC | PHASE3 |
| tozorakimab | AZN | IL-33 inhibitor | Antibody | SC | PHASE3 |
| Tezspire | AMGN, AZN | TSLP inhibitor | Antibody | SC | APPROVED |
| Breztri | AZN | ICS/LAMA/LABA combination | Inhaler | INHALATION | APPROVED |
| Dupixent | REGN | IL-4Rα inhibitor (monoclonal antibody) | Monoclonal antibody | SC | APPROVED |
Indications (2)
COPD with type 2 inflammation
COPD maintenance (inhaled therapy)
Upcoming Catalysts
Tozorakimab - COPD - Ph3 - Topline (OBERON)CLINICAL
AZNH1 2026
Dupixent - CSU - Ph3 Topline (LIBERTY-CSU CUPID)CLINICAL
REGN2026
Tezspire - EoE - Ph3 - ToplineCLINICAL
AZNH2 2026
Tezspire - COPD - Ph3 DataCLINICAL
AMGNH2 2026
Itepekimab - COPD - Ph3 Topline (AERIFY)CLINICAL
REGN2026-2027
Data from Supabase · Updated 2026-03-24